| | Term | Count | Genes |
| | Metabolic pathways | 14 | PLA2G10, PNMT, HSD17B1, HMGCR, CYP2C9, EPHX2, LSS, AKR1C3, CBR1, AKR1B1, HSD11B1, PLA2G2A, LTA4H, HPGDS | | PPAR signaling pathway | 11 | PPARA, APOA2, PPARD, RXRB, RXRA, PPARG, FABP3, FABP4, FABP7, FABP6, NR1H3 | | Arachidonic acid metabolism | 8 | AKR1C3, CBR1, PLA2G10, CYP2C9, PLA2G2A, EPHX2, LTA4H, HPGDS | | Metabolism of xenobiotics by cytochrome P450 | 8 | GSTM1, GSTM2, AKR1C2, CBR1, SULT2A1, CYP2C9, HSD11B1, AKR1C1 | | Steroid hormone biosynthesis | 6 | AKR1C3, AKR1C2, STS, HSD17B1, HSD11B1, AKR1C1 | | Chemical carcinogenesis | 6 | GSTM1, GSTM2, CBR1, SULT2A1, CYP2C9, HSD11B1 | | Bile secretion | 4 | SULT2A1, HMGCR, RXRA, NR1H4 | | Insulin resistance | 4 | NR1H2, PPARA, PIK3R1, NR1H3 | | Hepatitis C | 4 | PPARA, RXRA, PIK3R1, NR1H3 | | Nonalcoholic fatty liver disease (NAFLD) | 4 | PPARA, RXRA, PIK3R1, NR1H3 | | Linoleic acid metabolism | 3 | PLA2G10, CYP2C9, PLA2G2A | | Thyroid cancer | 3 | RXRB, RXRA, PPARG | | Non-small cell lung cancer | 3 | RXRB, RXRA, PIK3R1 |
|
|
